XML 55 R31.htm IDEA: XBRL DOCUMENT v3.22.1
REVENUES (Tables)
 3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Contract with Customer, Contract Asset
The following table summarizes our contract assets:
(in millions)March 31,
2022		December 31,
2021
Contract manufacturing services$47 $50 
Software sales42 45 
Bundled equipment and consumable medical products contracts111 100 
Contract assets$200 $195 
The following table summarizes the classification of contract assets and contract liabilities as reported in the condensed consolidated balance sheets:
(in millions)March 31,
2022		December 31,
2021
Prepaid expenses and other current assets$84 $84 
Other non-current assets116 111 
Contract assets$200 $195 
Accrued expenses and other current liabilities$166 $162 
Other non-current liabilities74 84 
Contract liabilities$240 $246 
The following table summarizes contract liability activity for the three months ended March 31, 2022. The contract liability balance represents the transaction price allocated to the remaining performance obligations.
Three Months Ended March 31, 2022
Balance at beginning of period$246 
New revenue deferrals116 
Revenue recognized upon satisfaction of performance obligations(122)
Balance at end of period$240 
Net Sales from Contracts with Customers by Global Business Unit
The following tables disaggregate our net sales from contracts with customers by product category between the U.S. and international:
Three Months Ended March 31,
20222021
(in millions)U.S.InternationalTotalU.S.InternationalTotal
Renal Care 1
$225 $669 $894 $216 $706 $922 
Medication Delivery 2
472 234 706 411 241 652 
Pharmaceuticals 3
157 364 521 200 352 552 
Clinical Nutrition 4
84 143 227 83 151 234 
Advanced Surgery 5
136 92 228 126 91 217 
Acute Therapies 6
68 120 188 81 126 207 
BioPharma Solutions 7
52 104 156 44 91 135 
Patient Support Systems 8
295 88 383 — — — 
Front Line Care 9
207 87 294 — — — 
Surgical Solutions 10
37 41 78 — — — 
Other 11
24 8 32 19 8 27 
Total Baxter$1,757 $1,950 $3,707 $1,180 $1,766 $2,946 
1Renal Care includes sales of our peritoneal dialysis (PD), hemodialysis (HD) and additional dialysis therapies and services.
2Medication Delivery includes sales of our intravenous (IV) therapies, infusion pumps, administration sets and drug reconstitution devices.
3Pharmaceuticals includes sales of our premixed and oncology drug platforms, inhaled anesthesia and critical care products and pharmacy compounding services.
4Clinical Nutrition includes sales of our parenteral nutrition (PN) therapies and related products.
5Advanced Surgery includes sales of our biological products and medical devices used in surgical procedures for hemostasis, tissue sealing and adhesion prevention.
6Acute Therapies includes sales of our continuous renal replacement therapies (CRRT) and other organ support therapies focused in the intensive care unit (ICU).
7BioPharma Solutions includes sales of contracted services we provide to various pharmaceutical and biopharmaceutical companies.
8Patient Support Systems includes sales of our connected care solutions: devices, software, communications and integration technologies.
9Front Line Care includes sales of our integrated patient monitoring and diagnostic technologies to help diagnose, treat and manage a wide variety of illness and diseases, including respiratory therapy, cardiology vision screening and physical assessment.
10Surgical Solutions includes sales of our surgical video technologies, tables, lights, pendants, precision positioning devices and other accessories.
11Other includes sales of miscellaneous product and service offerings.
Sales-type Lease, Lease Income The components of lease revenue for the three months ended March 31, 2022 and 2021 were:
(in millions)Three months ended March 31, 2022Three months ended March 31, 2021
Sales-type lease revenue$3 $6 
Operating lease revenue122 34 
Variable lease revenue20 17 
Total lease revenue$145 $57 
Operating Lease, Lease Income The components of lease revenue for the three months ended March 31, 2022 and 2021 were:
(in millions)Three months ended March 31, 2022Three months ended March 31, 2021
Sales-type lease revenue$3 $6 
Operating lease revenue122 34 
Variable lease revenue20 17 
Total lease revenue$145 $57